Life-changing Sjogren’s drug could reach the NHS after breakthrough trial
A patient with Sjogren’s syndrome experienced dramatic relief from monthly injections of ianalumab during a clinical trial, with signs of improved saliva production, less dryness and renewed energy. Experts say the therapy targets the underlying immune attack and could become the first targeted Sjogren’s treatment, potentially rolling out on the NHS in coming years. While promising, the drug can have side effects such as occasional low mood, and responses may vary between patients.
